Viking Therapeutics Inc. (VKTX)
Is Viking Therapeutics a Buy Right Now?
Viking Therapeutics (VKTX -3.01%) soared into the spotlight about a year ago when it delivered promising data on a drug candidate that aims to compete in an area of very high demand: weight loss. The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Should You Buy VKTX Stock Amid Renewed M&A Speculations?
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%.
3 Weight-Loss Drug Stocks to Watch
Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO) , and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most recognized names in the industry.
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Nearly a year ago, Viking Therapeutics (VKTX 3.50%) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss drug.
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.
Has the Bubble Burst for Viking Therapeutics Stock?
The excitement surrounding Viking Therapeutics (VKTX 3.49%) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value.
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why.
Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its weight-loss drugs. The post Viking Therapeutics Plummeted 10% On Its Earnings Report.
Viking Therapeutics, Inc. (VKTX) Q4 2024 Earnings Conference Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Stephanie Diaz - IR Manager Brian Lian - CEO and President Greg Zante - CFO Conference Call Participants Ryan Deschner - Raymond James Mike Ulz - Morgan Stanley Asim Rana - Truist Securities Jay Olson - Oppenheimer Annabel Samimy - Stifel Mayank Mamtani - B. Riley Securities Biren Amin - Piper Sandler Hardik Parikh - JPMorgan Andy Hsieh - William Blair Yale Jen - Laidlaw & Company Justin Zelin - BTIG Operator Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Prediction: This Pharma Stock Will Be the Best Performer in 2025
Market uncertainty can make nervous investors leery of investing in industries that are more speculative in nature, such as pharmaceuticals and biotechnology.
